CAS 475085-57-5
:2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]essigsäure
Beschreibung:
Prostacyclin (PGI
2
) is a potent vasorelaxant and inhibitor of platelet aggregation. It mediates its actions by binding to a specific G protein-
coupled receptor, the IP receptor, on the surface of endothelial cells, arterial smooth muscle, and platelets.
1
The IP receptor also participates in signal transduction of the pain response, cardioprotection, and inflammation.
2
,
3
,
4
,
5
MRE-
269 is the active form of the prodrug NS-
304. It is a potent and selective agonist for the human IP receptor with a K
i
value of 20 nM.
6
In contrast to PGI
2
, which has a half-
life of 30 seconds to a few minutes
in vivo
, plasma concentrations of MRE-
269 remain near peak levels for more than eight hours in rats and dogs.
6
Unlike the PGI
2
analogues, beraprost and iloprost, MRE-
269 lacks high affinity for the EP
3
receptor.
7
As a result, MRE-
269 induces vasodilation equally in large and small pulmonary arteries, whereas vasodilation of small arteries by beraprost and iloprost is reduced
via
EP
3
-
mediated vasoconstriction.
7
Formel:C25H29N3O3
InChl:InChI=1S/C25H29N3O3/c1-19(2)28(15-9-10-16-31-18-23(29)30)22-17-26-24(20-11-5-3-6-12-20)25(27-22)21-13-7-4-8-14-21/h3-8,11-14,17,19H,9-10,15-16,18H2,1-2H3,(H,29,30)
InChI Key:InChIKey=OJQMKCBWYCWFPU-UHFFFAOYSA-N
SMILES:N(CCCCOCC(O)=O)(C(C)C)C=1N=C(C(=NC1)C2=CC=CC=C2)C3=CC=CC=C3
Synonyme:- Acetic acid, [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-
- MRE 269
- Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-
- 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]acetic acid
- ACT 333679
- ACT-333679; MRE269; MRE 269; ACT333679; ACT 333679
- Selexipag impurity 6/Selexipag Acid/2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetic acid
- {4-[(5,6-Diphenyl-2-pyrazinyl)(isopropyl)amino]butoxy}acetic acid
- Selexipag internate 2
- 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid
- [4-[(5,6-DIPHENYLPYRAZINYL)(1-METHYLETHYL)AMINO]BUTOXY]-ACETIC ACID
- MRE-269 (ACT-333679)
- MRE-269 Selexipag Active Metabolite
- {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid
- 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid
- MRE-269 S
- Selexipag metabolite ACT-333679
- Slapag metabolite ACT-333679
- Weitere Synonyme anzeigen
Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
10 Produkte gefunden.
2-(4-((5,6-Diphenylpyrazin-2-Yl)(Isopropyl)Amino)Butoxy)Acetic Acid
CAS:2-(4-((5,6-Diphenylpyrazin-2-Yl)(Isopropyl)Amino)Butoxy)Acetic AcidFormel:C25H29N3O3Reinheit:98%Molekulargewicht:419.52[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid
CAS:Formel:C25H29N3O3Reinheit:98%Farbe und Form:SolidMolekulargewicht:419.5161Selexipag Metabolite (MRE-269, ACT-333679)
CAS:Formel:C25H29N3O3Farbe und Form:Pale Yellow SolidMolekulargewicht:419.53MRE-269
CAS:2-(4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acidFormel:C25H29N3O3Reinheit:98%Molekulargewicht:419.52MRE-269
CAS:MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug, used for the treatment of pulmonary arterial hypertension.Formel:C25H29N3O3Reinheit:98.25%Farbe und Form:White SolidMolekulargewicht:419.52MRE-269-d10
CAS:Kontrolliertes ProduktFormel:C25D10H19N3O3Farbe und Form:NeatMolekulargewicht:429.578







